Agreements governing your use of Emergobyul.com
Optimize your FDA Pre-Sub process and know when to use the Pre-Sub option for better regulatory outcomes.
A press release by the European Commission announced its 2025 Commission Work Program. The primary message: “Moving forward together: A Bolder, Simpler, Faster Union”.
Medical device manufacturers doing business in the European Union (EU) will want to review the most recent version of the MDCG 2019-6 Questions and Answers (Q&A) document, which represents the most significant update to date regarding notified bodies.
The European Commission has announced a pilot program that may shorten the time to market for medical device manufacturers in Europe. The coordinated assessment procedure is a mechanism to permit a single application to multiple member states in which the Clinical Investigations and Performance Studies (CI/PS) would be conducted.
Gain insights into U.S. FDA regulatory classifications and testing requirements for introducing medical devices to the market, including high-risk devices.
The IMDRF has released two new key medical device software guidance documents.
An Emergo by UL human factors specialist discusses the top use errors observed when evaluating pen-injector interactions during a usability study, and how manufacturers can work towards mitigating such use errors.
Emergo by UL Human Factors Specialists discuss the benefits of running pilot tests prior to conducting usability studies.